牛牛AI助理已提取核心訊息
On February 20, 2024, a significant filing was made with the United States Securities and Exchange Commission (SEC) by New Dimensions Trading Ltd. and Jacob Safier regarding their holdings in T2 Biosystems, Inc. The Schedule 13G filing indicates that New Dimensions Trading Ltd., a company organized under the laws of the Cayman Islands, and Jacob Safier, a United States citizen, collectively own 350,000 shares of T2 Biosystems' common stock, which represents 7.1% of the company's class of securities. This level of ownership triggers the requirement for the Schedule 13G filing under SEC rules. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of T2 Biosystems, nor were they held in connection with any transaction having that purpose or effect. The filing was signed and dated March 11, 2024, by Chana Edelstein, Director of New Dimensions Trading Ltd., and Jacob Safier, confirming the accuracy of the information provided.
On February 20, 2024, a significant filing was made with the United States Securities and Exchange Commission (SEC) by New Dimensions Trading Ltd. and Jacob Safier regarding their holdings in T2 Biosystems, Inc. The Schedule 13G filing indicates that New Dimensions Trading Ltd., a company organized under the laws of the Cayman Islands, and Jacob Safier, a United States citizen, collectively own 350,000 shares of T2 Biosystems' common stock, which represents 7.1% of the company's class of securities. This level of ownership triggers the requirement for the Schedule 13G filing under SEC rules. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of T2 Biosystems, nor were they held in connection with any transaction having that purpose or effect. The filing was signed and dated March 11, 2024, by Chana Edelstein, Director of New Dimensions Trading Ltd., and Jacob Safier, confirming the accuracy of the information provided.
2024年2月20日，New Dimensions Trading Ltd.和Jacob Safier就其持有的T2 Biosystems, Inc.向美國證券交易委員會（SEC）提交了一份重要文件。附表13G文件顯示，根據開曼群島法律組建的公司新維度貿易有限公司和美國公民雅各布·薩菲爾共擁有T2 Biosystems公司35萬股普通股，佔7.1％ 該公司的證券類別。這種所有權級別觸發了美國證券交易委員會規則對附表13G申報的要求。該文件稱，收購這些股份不是爲了改變或影響T2 Biosystems的控制權，也不是與任何具有該目的或效果的交易有關而持有的。該文件由新維度貿易有限公司董事查娜·愛德斯坦和雅各布·薩菲爾於2024年3月11日簽署並註明日期，證實了所提供信息的準確性。
2024年2月20日，New Dimensions Trading Ltd.和Jacob Safier就其持有的T2 Biosystems, Inc.向美國證券交易委員會（SEC）提交了一份重要文件。附表13G文件顯示，根據開曼群島法律組建的公司新維度貿易有限公司和美國公民雅各布·薩菲爾共擁有T2 Biosystems公司35萬股普通股，佔7.1％ 該公司的證券類別。這種所有權級別觸發了美國證券交易委員會規則對附表13G申報的要求。該文件稱，收購這些股份不是爲了改變或影響T2 Biosystems的控制權，也不是與任何具有該目的或效果的交易有關而持有的。該文件由新維度貿易有限公司董事查娜·愛德斯坦和雅各布·薩菲爾於2024年3月11日簽署並註明日期，證實了所提供信息的準確性。
有用
沒用